Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.14694
Abstract: Key Points Question Are commonly used treatments for metastatic castration-resistant prostate cancer (mCRPC) associated with a decline in cognitive function in older men? Findings This cohort study followed up 198 men aged 65 years or… read more here.
Keywords: older men; prostate cancer; metastatic castration; castration resistant ... See more keywords
The role of epithelial–mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel‐resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12030
Abstract: Docetaxel is the main treatment for advanced castration‐resistant prostate cancer; however, resistance eventually occurs. The development of intratumoral drug‐resistant subpopulations possessing a cancer stem cell (CSC) morphology is an emerging mechanism of docetaxel resistance, a… read more here.
Keywords: prostate cancer; docetaxel resistant; cancer; resistant prostate ... See more keywords
AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12529
Abstract: The androgen receptor splice variant (AR‐V) 7 in circulating tumor cells (CTCs) is a predictor for resistance to anti‐AR‐targeted treatment, but not to taxane‐based chemotherapy in metastatic castration‐resistant prostate cancer (mCRPC). In this study, we… read more here.
Keywords: prostate; tumor cells; prostate cancer; circulating tumor ... See more keywords
The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13320
Abstract: The success of the PROfound, IPATential150, and TheraP trials promoted the transition from sequential treatment to therapeutic targets (TTs)‐guided precision treatment in metastatic castration‐resistant prostate cancer (mCRPC). The objective of this study was to evaluate… read more here.
Keywords: prevalence; prostate; resistant prostate; castration resistant ... See more keywords
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3806
Abstract: Metastatic castration‐resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to have antineoplastic properties. On the basis of previous phase I and phase II studies, we investigated whether the association of… read more here.
Keywords: phase; docetaxel plus; metastatic castration; castration resistant ... See more keywords
Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5262
Abstract: Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in castration‐resistant… read more here.
Keywords: prostate cancer; resistant prostate; real world; castration resistant ... See more keywords
Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5313
Abstract: Understanding how patients perceive the efficacy, safety, and administrative burden of treatments for metastatic castration‐resistant prostate cancer (mCRPC) can facilitate shared‐decision making for optimal management. This study sought to elicit patient preferences for mCRPC treatments… read more here.
Keywords: prostate cancer; cancer mcrpc; resistant prostate; castration resistant ... See more keywords
The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5333
Abstract: Metastatic castration‐resistant prostate cancer (mCRPC) is a genetically heterogeneous disease with a poor prognosis. The prevalence of mutations in homologous recombination repair (HRR) pathway genes, including BRCA1/2, as well as treatment patterns and clinical outcomes,… read more here.
Keywords: prostate cancer; resistant prostate; castration resistant; metastatic castration ... See more keywords
Differential adoption of castration‐resistant prostate cancer treatment across facilities in a national healthcare system
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5490
Abstract: Over the past decade, abiraterone and enzalutamide have largely replaced ketoconazole as oral treatments for castration‐resistant prostate cancer (CRPC). We investigated the differential adoption of abiraterone and enzalutamide across facilities in a national healthcare system… read more here.
Keywords: prostate cancer; differential adoption; across facilities; resistant prostate ... See more keywords
Biomarkers for predicting abiraterone treatment outcome and selecting alternative therapies in castration-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2582
Abstract: Approximately One-third of metastatic castration-resistant prostate cancer (mCRPC) patients exhibited primary abiraterone resistance. To identify alternative treatment for abiraterone non-responders, we performed drug discovery analyses using the L1000 database using differentially expressed genes identified in… read more here.
Keywords: cancer; alternative therapies; castration resistant; abiraterone ... See more keywords
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration‐Resistant Prostate Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.907
Abstract: The testis‐specific Y‐encoded‐like protein (TSPYL) gene family includes TSPYL1 to TSPYL6. We previously reported that TSPYL5 regulates cytochrome P450 (CYP) 19A1 expression. Here we show that TSPYLs, especially TSPYL 1, 2, and 4, can regulate… read more here.
Keywords: response; cyp3a4 expression; metastatic castration; expression ... See more keywords